Takara Bio plans to execute a share consolidation on May 20, 2026, and will delist from the stock exchange on the same day. The consolidation ratio is set at 15,332,374 shares to 1 share, reducing the issued shares from 120,415,300 to 6 shares. Procedures for handling fractional shares and amendments to the articles of incorporation are also scheduled.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4974","jir_company_name":"Takara Bio Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4974-20260520-01.pdf","jir_short_summary":"Takara Bio plans to execute a share consolidation on May 20, 2026, and will delist from the stock exchange on the same day. The consolidation ratio is set at 15,332,374 shares to 1 share, reducing the issued shares from 120,415,300 to 6 shares. Procedures for handling fractional shares and amendments to the articles of incorporation are also scheduled.","jir_summary":"### Overview of Share Consolidation and Delisting\nTakara Bio will implement a share consolidation on May 20, 2026, with a ratio of 15,332,374 shares to 1 share. This will reduce the total issued shares from 120,415,300 to 6 shares. The delisting from the Tokyo Stock Exchange is scheduled for June 12, 2026, and procedures for the amendment of articles of incorporation and handling fractional shares are in progress. The purpose of the consolidation is to streamline shares and prepare for delisting.\n\n### Impact on Shareholders and Future Schedule\nIn cases where fractional shares are generated, proceeds from their sale will be distributed to shareholders. The consolidation will take effect on June 16, 2026, followed by the sale of fractional shares and partial amendments to the articles of incorporation. Following delisting, trading of shares will cease, and shareholders will receive guidance on subsequent steps. The procedures for consolidation and delisting will proceed with court approval.","jir_financial_highlights":"Total Issued Shares: 120,415,300 shares (before consolidation) (Reduced to 6 shares due to consolidation)\nConsolidation Ratio: 15,332,374 shares to 1 share (Significant decrease in number of shares)\nScheduled Delisting Date: June 12, 2026 (Procedures for delisting underway)","jir_category":"","jir_hashtags":"#TakaraBio, #ShareConsolidation, #JapaneseStocks","jir_key_figures":"Total issued shares: 120,415,300 shares (before consolidation)\nConsolidation ratio: 15,332,374 shares to 1 share\nScheduled delisting date: June 12, 2026","jir_meta_title":"\u3010Takara Bio\u3011 Share Consolidation and Delisting | May 2026","jir_meta_description":"Takara Bio plans to execute a share consolidation on May 20, 2026, with delisting scheduled on the same day. This report details the consolidation ratio, schedule, and impact on shareholders.","jir_og_title":"\u3010Takara Bio\u3011 Share Consolidation and Delisting | May 2026","jir_og_description":"Takara Bio will conduct a share consolidation on May 20, 2026, and is scheduled to delist. Details on shareholder impact and future schedule are provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9678,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-53208","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n